The European Medicines Agency Monday called for strong warnings to be issued to doctors and parents against giving two types of antidepressant drugs to children and adolescents. The European Union regulator recommended that the drugs shouldn't be used by young patients except under approved conditions.
A review of serotonin-selective reuptake inhibitors, which include Prozac and Paxil, and serotonin-norepinephrine reuptake inhibitors, such as Effexor, looked at the potential risk of suicidal behavior in children and adolescents treated with these products.
The medicines agency said its Committee for Medicinal Products for Human Use concluded last week that suicide-related behavior and hostility were more frequently observed in clinical trials among children and adolescents treated with these antidepressants than those treated with placebo.
Source
A review of serotonin-selective reuptake inhibitors, which include Prozac and Paxil, and serotonin-norepinephrine reuptake inhibitors, such as Effexor, looked at the potential risk of suicidal behavior in children and adolescents treated with these products.
The medicines agency said its Committee for Medicinal Products for Human Use concluded last week that suicide-related behavior and hostility were more frequently observed in clinical trials among children and adolescents treated with these antidepressants than those treated with placebo.
Source